Corcept director sells 10,000 shares via trust

Director James N. Wilson’s trust sold 10,000 CORT shares under a Rule 10b5-1 plan and reported additional indirect holdings in two 2025 Grantor Retained Annuity Trusts.

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) director James N. Wilson reported indirect sales of a total of 10,000 shares of common stock on September 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust. The shares were sold in open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026, at weighted average prices between $109.66 and $111.705 per share. Wilson has voting power over the trust’s shares under voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest. The filing also reports indirect holdings of 200,000 shares each in the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust as of September 15, 2026.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 5 txns

Insider WILSON JAMES N

Role Director

Sold 10,000 shs ($1.11M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F5	6,800	$110.2698	$750K
Sale	Common Stock F1, F3, F5	400	$110.8363	$44K
Sale	Common Stock F1, F4, F5	2,800	$111.7039	$313K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,064,543 shares (Indirect, James N. Wilson and Pamela D. Wilson Trust); Common Stock — 200,000 shares (Indirect, James N. Wilson 2025 Grantor Retained Annuity Trust); Common Stock — 200,000 shares (Indirect, Pamela D. Wilson 2025 Grantor Retained Annuity Trust)

Footnotes (5)

1. F1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
2. F2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. F5. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Key Figures

Shares sold on September 15, 2026: 10,000 shares First sale block: 6,800 shares at $110.2698 per share Second sale block: 400 shares at $110.8363 per share +5 more

8 metrics

Shares sold on September 15, 2026 10,000 shares Total indirect sales by the James N. Wilson and Pamela D. Wilson Trust

First sale block 6,800 shares at $110.2698 per share Open-market sale on September 15, 2026

Second sale block 400 shares at $110.8363 per share Open-market sale on September 15, 2026

Third sale block 2,800 shares at $111.7039 per share Open-market sale on September 15, 2026

Price range for first block $109.66–$110.64 per share Actual sale price range for 6,800 shares

Price range for second block $110.665–$111.095 per share Actual sale price range for 400 shares

Price range for third block $111.70–$111.705 per share Actual sale price range for 2,800 shares

Indirect GRAT holdings 200,000 shares in each of two trusts Holdings in the 2025 Grantor Retained Annuity Trusts as of September 15, 2026

Key Terms

Rule 10b5-1 plan, Grantor Retained Annuity Trust, weighted average sale price, voting agreements

4 terms

Rule 10b5-1 plan regulatory

"transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Grantor Retained Annuity Trust financial

"James N. Wilson 2025 Grantor Retained Annuity Trust"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold"

voting agreements regulatory

"has voting power over the shares held by the ... Trust pursuant to voting agreements"

A voting agreement is a legally binding deal where shareholders promise to cast their votes the same way on corporate matters, such as choosing directors or approving big transactions. Think of it like a neighborhood group agreeing to support the same candidate so they can decide how the block is run; for investors, these pacts can change who controls a company, influence strategy and risk, and affect the value and liquidity of shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CORT director James N. Wilson report on this Form 4?

He reported indirect sales totaling 10,000 shares of Corcept Therapeutics (CORT) common stock on September 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust in open-market transactions.

At what prices were the CORT shares sold in James N. Wilson’s September 15, 2026 transactions?

The Form 4 reports weighted average sale prices of $110.2698, $110.8363, and $111.7039 per share, with actual sale prices ranging from $109.66 to $111.705 per share across the three sale groups.

Were James N. Wilson’s CORT share sales made under a Rule 10b5-1 plan?

Yes. A footnote states the September 15, 2026 transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2026 that was in effect at the time of the sales.

How are the sold CORT shares held in relation to James N. Wilson?

The 10,000 sold shares were held indirectly through the James N. Wilson and Pamela D. Wilson Trust. Wilson has voting power via voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.

What additional CORT holdings are reported for James N. Wilson on this Form 4?

The filing reports indirect holdings of 200,000 shares of CORT common stock in the James N. Wilson 2025 Grantor Retained Annuity Trust and 200,000 shares in the Pamela D. Wilson 2025 Grantor Retained Annuity Trust as of September 15, 2026.

Does the Form 4 indicate whether James N. Wilson directly owns any CORT shares?

This Form 4 describes indirect holdings through trusts and does not list any direct ownership position for James N. Wilson. All reported positions are held through the named trusts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:31 PM Accepted by SEC EDGAR 09/16/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON JAMES N

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		S(1)		6,800	D	$110.2698(2)	1,067,743	I	James N. Wilson and Pamela D. Wilson Trust(5)
Common Stock	09/15/2026		S(1)		400	D	$110.8363(3)	1,067,343	I	James N. Wilson and Pamela D. Wilson Trust(5)
Common Stock	09/15/2026		S(1)		2,800	D	$111.7039(4)	1,064,543	I	James N. Wilson and Pamela D. Wilson Trust(5)
Common Stock								200,000	I	James N. Wilson 2025 Grantor Retained Annuity Trust
Common Stock								200,000	I	Pamela D. Wilson 2025 Grantor Retained Annuity Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)